Title and Organization:
Ms. Hilleman has served as a Chief Financial Officer for over 20 years in the life sciences industry, including biopharmaceutical, renewable and med tech companies. In that capacity, she was involved with taking 5 companies public and raising over $1 billion in equity and debt financing. Ms. Hilleman is presently CFO of Intersect ENT (NASDAQ: XENT), a medical device company with commercial products for the treatment of chronic sinusitis. Previously, she served as CFO at companies including Amyris (NASDAQ: AMRS), a renewable products company operating in California and Brazil, Symyx Technologies, (NASDAQ: SMMX, acquired), which provided automated high through-put research services, software and instrumentation, and biopharma companies Geron (NASDAQ GERN) and Cytel Corporation (NASDAQ: CYTL, acquired). Ms. Hilleman currently serves on board and audit committees of Novocure (NASDAQ:NVCR) and Minerva Neurosciences (NASDAQ: NERV). She previously served as a member of the Board of Directors and Chair of the Audit Committee of Xenoport, Inc. (NASDAQ: XNPT, acquired), a commercial biopharma company, for over ten years, from IPO through acquisition. In addition, she has served on the Board of Trustees of GeoHazards International and on the Advisory Board of the Stanford Equestrian Center. Jeri holds an A.B. from Brown University where she was in the medical sciences program and an M.B.A. from the Wharton Graduate School of Business. She is a member of the 1999 class of Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute.